NOVARTIS - KESIMPTA
NOVARTIS PRESENTED STRONG EXTENSION STUDY DATA OF KESIMPTA AT THE EAN 2022 CONGRESS
Novartis announced new data from Phase 3 ASCLEPIOS I/II trials and ALITHIOS extension study of Kesimpta (ofatumumab) in patients with relapsing forms of multiple sclerosis.
The new data showed that 80% of patients with RMS with continuous treatment with Kesimpta had no evidence of disease activity (NEDA-3) versus 50% in patients who were switched to Kesmpta after having an initial treatment with teriflunomide. Further, Novartis announced that treatment with Kesimpta improved cognitive processing speed (CPS) compared to patients on teriflunomide.
Kesimpta is an anti-CD20 monoclonal antibody approved for treating adults with relapsing forms of multiple sclerosis. It can be administered once every month.
BMS - ZEPOSIA
BMS PRESENTED NEW ZEPOSIA DATA IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
BMS presented the new post-hoc data of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis. The company presented the Phase 3 DAYBREAK open-label extension (OLE) and Phase 3 SUNBEAM trials.
In the DAYBREAK open-label extension trial, treatment with Zeposia resulted in improved or preserved cognitive function, nearly 80% in patients with high thalamic volume.
Zeposia is taken orally and acts by binding to S1P receptors 1 and 5.